RE:RE:RE:RE:RE:RE:Stay focused on the factsI can't remember off the top of my head if they specifically said all was going smoothly but they certainly alluded to that being the case. But seeing neutropenia is what the phase 1a was looking for so seeing it would be normal. Basically a dose escalation study is trying to determine how much of a drug can be tolerated before trouble arises so finding things like neutrpenia is the goal of the study and seeing it is normal.
PWIB123 wrote: Did they actually say all went smoothly? I don't recall hearing that, especially considering they released and acknowledged the neutropenia. I do remember them saying that the things they were seeing were consistent with preclinical.
canadapiet wrote: And they lied again!!!!!!!
They said the P1a all went smoothly, just like in the preclinicals............!
Look at where we are now..........
How long are the "people in the know" saying that there is "HOPE" ?????
Well, let us all "HOPE" that in the near future (?????again....) we can set a new high !!
Momo25 - (3/23/2022 9:54:30 AM)
RE:RE:RE:Stay focused on the facts
I bought THTX when Trogarzo was lunched. At that time Dubuc talked about a potential of at least 1 billion revenue. Then everything becomes inconsistent. Legacy drugs are covering for the costs only. NASH needs huge investment and big pharmas who are making money like ever are reluctant to put a penny in this program. Oncology was brought to the table since they bought katana and the results up to now are very tiny, if not insignificant.
I averaged down many times and i am still a bit below 6$ and I took a hit of 49k by selling half of my THTX portfolio. Many shhareholders are in the same situation where I am. This is our reality today. The rest is bla..bla